Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2025-12-25 @ 9:31 PM
Study NCT ID:
NCT06157151
Status:
RECRUITING
Last Update Posted:
2025-11-14
First Post:
2023-11-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Sponsor:
Precigen, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-03-21
Start Date Type:
ACTUAL
Primary Completion Date:
2028-01-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-01-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-27
First Submit QC Date:
None
Study First Post Date:
2023-12-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-13
Last Update Post Date:
2025-11-14
Last Update Post Date Type:
ESTIMATED